Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA9084-LBA9084
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Field Control ◽  
Melanoma Patients ◽  
Final Text ◽  
Financial Relationships

LBA9084 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (18_suppl) ◽  
pp. LBA9084-LBA9084 ◽  
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
High Risk ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Randomized Study ◽  
Regional Recurrence ◽  
Nodal Basin ◽  
Increased Risk ◽  
Field Control ◽  
Melanoma Patients

LBA9084 Background: Adjuvant radiotherapy (RT) is an option for patients with isolated regional recurrence of melanoma considered to be at high risk of further regional recurrence after lymphadenectomy. This is the first completed study to assess the effects of RT on regional recurrence, survival, morbidity and quality of life (QOL) in these patients. Methods: Multicenter randomized study of patients with isolated regional recurrence at increased risk (>25%) of regional recurrence. Eligibile patients included ≥1 parotid, ≥ 2 cervical or axillary or ≥ 3 groin nodes or extra nodal spread of tumor or maximum metastatic node diameter ≥3cm in neck or axilla or ≥4cm in the groin. Patients were randomized to observation or regional nodal basin RT (48Gy in 20 fractions) after lymphadenectomy. Regional recurrence was the primary end point and morbidity, QOL, patterns of relapse, disease free and overall survival were secondary end points. The target sample size was 220 patients, which would enable a difference in 3 year regional relapse (cumulative incidence) rates of 30% versus 15% to be detected with a power of 80% (using a two sided logrank test at the 5% level of significance). Results: 250 pts were randomized from 16 centers from March 2002 to September 2007. There were 123 in the RT group and 127 in OBS group. 2 pts withdrew consent and 31 were excluded from analysis of the main objective following an independent blinded review of eligibility compliance by two reviewers. 227 pts were available for analysis of the main objective (109 RT, 108 OBS). Median follow-up was 27 mo. There was a statistically significant improvement in lymph node field control with radiotherapy, 20 RT pts and 34 OBS pts relapsed (HR 1.77 1.02–3.08 p=0.041). Median survival times were 2.6 years (RT) and 3.9 years (OBS) p=0.14. Conclusions: Adjuvant RT improved regional control in melanoma patients at high risk of regional relapse after lymphadenectomy. An effect on survival was not demonstrated. No significant financial relationships to disclose.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1-1
Author(s):  
G. J. Rustin ◽  
M. E. van der Burg
Keyword(s):  
Ovarian Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Treatment ◽  
Clinical Indicators ◽  
Delayed Treatment ◽  
Ca125 Level ◽  
Final Text ◽  
Financial Relationships

1 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5508-LBA5508
Author(s):  
S. Pignata ◽  
G. Scambia ◽  
A. Savarese ◽  
R. Sorio ◽  
E. Breda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Multicenter Trial ◽  
Final Text ◽  
Financial Relationships

LBA5508 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA509-CRA509
Author(s):  
V. Dezentje ◽  
N. J. Van Blijderveen ◽  
H. Gelderblom ◽  
H. Putter ◽  
M. P. Van Herk-Sukel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Pharmacoepidemiological Study ◽  
Final Text ◽  
Financial Relationships

CRA509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4009-LBA4009 ◽  
Author(s):  
R. James ◽  
S. Wan ◽  
R. Glynne-Jones ◽  
D. Sebag-Montefiore ◽  
L. Kadalayil ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Randomized Trial ◽  
Cell Carcinoma ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Squamous Cell ◽  
Final Text

LBA4009 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4-LBA4 ◽  
Author(s):  
N. Wolmark ◽  
G. Yothers ◽  
M. J. O'Connell ◽  
S. Sharif ◽  
J. N. Atkins ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon ◽  
Final Text ◽  
Financial Relationships

LBA4 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4003-LBA4003
Author(s):  
Thierry Conroy ◽  
Marie-Pierre Galais ◽  
Jean Luc Raoul ◽  
Olivier Bouche ◽  
Sophie Gourgou-Bourgade ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Definitive Chemoradiotherapy ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA4003 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4004-LBA4004 ◽  
Author(s):  
Gary William Middleton ◽  
Juan W. Valle ◽  
Jonathan Wadsley ◽  
David Propper ◽  
Fareeda Y. Coxon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Locally Advanced ◽  
Phase Iii ◽  
Metastatic Pancreatic Cancer ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA4004 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document